Low-dose glucocorticoid therapy complement the pituitary-adrenocortical system and reduce anxiety and insomnia in myasthenia gravis patients

• In: Posters
• At: Amsterdam (the Netherlands) (2012)
• Type: Poster
• Poster code: HPS-P-106
• By: TANAKA, Sachiko (Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan)
• Co-author(s): Akashi, T. (Tokyo Medical University, Tokyo, Japan)
  Itoh, S. (Tokyo Medical University, Tokyo, Japan)
  Masuda, M. (Tokyo Medical University, Tokyo, Japan)
  Utsumi, H. (Tokyo Medical University, Tokyo, Japan)
  Kasahara, C. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  Ochiai, Y. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  Yamamoto, M. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  Takeuchi, H. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  Unezaki, S. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  Hirano, T. (Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan)
  
• Abstract:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  1. 
     Background Myasthenia gravis is an autoimmune disorder generally mediated by antibodies against the acetylcholine receptors of the skeletal muscles. Depending on the disease burden myasthenia gravis patients may experience chronic dysregulation of both the hormonal stress-axis and the immune system, but also leading to secondary psychopathological
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login